STOCK TITAN

Codexis to Report Third Quarter 2023 Financial Results on November 2

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Codexis, Inc. to report Q3 2023 financial results and host conference call on November 2, 2023
Positive
  • Codexis will report its financial results for Q3 2023 on November 2, 2023
  • The company will provide a business update during the conference call
Negative
  • None.

REDWOOD CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the third quarter of 2023 on Thursday, November 2, 2023, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update.

Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing (877) 705-2976 (domestic) or (201) 689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing (877) 660-6853 (domestic) or (201) 612-7415 (international), access ID #13726635.

About Codexis

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.

For More Information

Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com

Media Contact
Lauren Musto
(781) 572-1147
media@codexis.com


FAQ

When will Codexis report its financial results for Q3 2023?

Codexis will report its financial results for Q3 2023 on November 2, 2023.

What time will the conference call and webcast take place?

The conference call and webcast will take place at 4:30 pm Eastern Time.

How can participants access the live webcast?

Participants may access the live webcast on the Codexis Investor Relations website.

How long will the webcast be available?

The webcast will be archived for 90 days on the Codexis Investor Relations website.

How can participants access the live call?

Participants can access the live call by dialing (877) 705-2976 (domestic) or (201) 689-8798 (international).

How long will the telephone replay be available?

The telephone replay will be available for 48 hours by dialing (877) 660-6853 (domestic) or (201) 612-7415 (international), access ID #13726635.

Codexis, Inc.

NASDAQ:CDXS

CDXS Rankings

CDXS Latest News

CDXS Stock Data

218.64M
63.61M
3.22%
82.74%
3.39%
Paint and Coating Manufacturing
Manufacturing
Link
United States of America
REDWOOD CITY

About CDXS

codexis, inc. is a leading protein engineering company applying innovative technologies to unlock the power of proteins™. our proprietary codeevolver® technology platform enables the rapid development and production of highly optimized proteins, custom-designed for your application. codexis’ revolutionary approach to protein engineering starts with an understanding of the desired performance specifications and optimizes a protein specifically to fit these requirements. you get precisely the protein you need for the job you want it to do. guided by proprietary artificial intelligence software and advanced high-throughput screening systems, codexis is able to efficiently generate and introduce function-driven mutations to rapidly improve a protein for its target application. since 2002, codexis’ in-house biochemists, biologists and bioinformatics experts have worked closely with our clients to advance the technologies for protein optimization and production, enabling breakthrough develop